Is there a CSF biomarker profile related to depression in elderly women?

Psychiatry Research

Volumn 176, Issue 2-3, 2010, Pages 174-178

  Gudmundsson, Pia ^a   Skoog, Ingmar ^a   Waern, Margda ^a   Blennow, Kaj ^a   Zetterberg, Henrik ^a   Rosengren, Lars ^a   Gustafson, Deborah ^a,b  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

Amyloid beta 42; Biomarker; CSF serum albumin ratio; Neurofilament; Population based; Total Tau

Indexed keywords

ALBUMIN; AMYLOID BETA PROTEIN[1-42]; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BIOLOGICAL MARKER; GLIAL FIBRILLARY ACIDIC PROTEIN; NEUROFILAMENT PROTEIN; TAU PROTEIN;

AGE; AGED; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE ASSOCIATION; DISEASE DURATION; DYSTHYMIA; FEMALE; HUMAN; LUMBAR PUNCTURE; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; NERVE DEGENERATION; NEUROPATHOLOGY; NEUROPSYCHIATRY; PREVALENCE; PRIORITY JOURNAL;

AGED; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; DEPRESSION; FEMALE; GERIATRIC ASSESSMENT; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; LOGISTIC MODELS; NEUROFILAMENT PROTEINS; PEPTIDE FRAGMENTS;

EID: 77949776051     PISSN: 01651781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.psychres.2008.11.012     Document Type: Article

References (49)

1. Alexopoulos G.S., Meyers B.S., Young R.C., Campbell S., Silbersweig D., Charlson M. Vascular depression hypothesis. Archives of General Psychiatry 1997, 54:915-921.
2. Arean P.A., Reynolds C.F. The impact of psychosocial factors on late-life depression. Biological Psychiatry 2005, 58:277-282.
3. Arjona A.A., Pooler A.M., Lee R.K., Wurtman R.J. Effect of a 5-HT(2C) serotonin agonist, dexnorfenfluramine, on amyloid precursor protein metabolism in guinea pigs. Brain Research 2002, 951:135-140.
4. Aurell A., Rosengren L.E., Karlsson B., Olsson J.E., Zbornikova V., Haglid K.G. Determination of S-100 and glial fibrillary acidic protein concentrations in cerebrospinal fluid after brain infarction. Stroke 1991, 22:1254-1258.
5. Bayard-Burfield L., Alling C., Blennow K., Jonsson S., Traskman-Bendz L. Impairment of the blood-CSF barrier in suicide attempters. European Neuropsychopharmacology 1996, 6:195-199.
6. Blennow K., Galasko D. Cerebrospinal fluid biomarkers for Alzheimer's disease: their role in Clinical Chemistry. Biochimica Clinica 2000, 24:158-162.
7. Blennow K., Fredman P., Wallin A., Gottfries C.G., Langstrom G., Svennerholm L. Protein analyses in cerebrospinal fluid. I. Influence of concentration gradients for proteins on cerebrospinal fluid/serum albumin ratio. European Neurology 1993, 33:126-128.
8. Breslau N., Schultz L., Peterson E. Sex differences in depression: a role for preexisting anxiety. Psychiatry Research 1995, 58:1-12.
9. Castren E. Is mood chemistry?. Nature Reviews 2005, 6:241-246.
10. Cereseto M., Reines A., Ferrero A., Sifonios L., Rubio M., Wikinski S. Chronic treatment with high doses of corticosterone decreases cytoskeletal proteins in the rat hippocampus. European Journal of Neuroscience 2006, 24:3354-3364.
11. Damadzic R., Bigelow L.B., Krimer L.S., Goldenson D.A., Saunders R.C., Kleinman J.E., Herman M.M. A quantitative immunohistochemical study of astrocytes in the entorhinal cortex in schizophrenia, bipolar disorder and major depression: absence of significant astrocytosis. Brain Research Bulletin 2001, 55:611-618.
12. Davis S., Thomas A., Perry R., Oakley A., Kalaria R.N., O'Brien J.T. Glial fibrillary acidic protein in late life major depressive disorder: an immunocytochemical study. Journal of Neurology, Neurosurgery and Psychiatry 2002, 73:556-560.
13. de Jong D., Jansen R.W., Pijnenburg Y.A., van Geel W.J., Borm G.F., Kremer B.P., Verbeek M.M. CSF neurofilament proteins in the differential diagnosis of dementia. Journal of Neurology, Neurosurgery and Psychiatry 2007, 78:936-938.
14. Dhaenen H. Imaging the serotonergic system in depression. European Archives of Psychiatry and Clinical Neuroscience 2001, 251(Suppl 2):II76-II80.
15. Dziegielewska K.M., Ek J., Habgood M.D., Saunders N.R. Development of the choroid plexus. Microscopy Research and Technique 2001, 52:5-20.
16. Fatemi S.H., Laurence J.A., Araghi-Niknam M., Stary J.M., Schulz S.C., Lee S., Gottesman I.I. Glial fibrillary acidic protein is reduced in cerebellum of subjects with major depression, but not schizophrenia. Schizophrenia Research 2004, 69:317-323.
17. Gudmundsson P., Skoog I., Waern M., Blennow K., Pálsson S., Rosengren L., Gustafson D. The relationship between cerebrospinal fluid biomarkers and depression in elderly women. American Journal of Geriatric Psychiatry 2007, 15:832-838.
18. Guéz M., Hildingsson C., Rosengren L., Karlsson K., Toolanen G. Nervous tissue damage markers in cerebrospinal fluid after cervical spine injuries and whiplash trauma. Journal of Neurotrauma 2003, 20:853-858.
19. Gustafson D., Skoog I., Rosengren L., Zetterberg H., Blennow K. Cerebrospinal fluid beta-amyloid 1-42 concentration may predict cognitive decline in older women. Journal of Neurology, Neurosurgery, and Psychiatry 2007, 78:461-464.
20. Hampel H., Kotter H.U., Moller H.J. Blood-cerebrospinal fluid barrier dysfunction for high molecular weight proteins in Alzheimer disease and major depression: indication for disease subsets. Alzheimer Disease and Associated Disorders 1997, 11:78-87.
21. Hindmarch I. Expanding the horizons of depression: beyond the monoamine hypothesis. Human Psychopharmacology 2001, 16:203-218.
22. Hoffman P.N., Griffin J.W., Price D.L. Control of axonal caliber by neurofilament transport. The Journal of Cell Biology 1984, 99:705-714.
23. Johnston-Wilson N.L., Sims C.D., Hofmann J.P., Anderson L., Shore A.D., Torrey E.F., Yolken R.H. Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium. Molecular Psychiatry 2000, 5:142-149.
24. Kabanda A., Goffin E., Bernard A., Lauwerys R., van Ypersele de Strihou C. Factors influencing serum levels and peritoneal clearances of low molecular weight proteins in continuous ambulatory peritoneal dialysis. Kidney International 1995, 48:1946-1952.
25. Karlsson J.E., Rosengren L.E., Haglid K.G. Quantitative and qualitative alterations of neuronal and glial intermediate filaments in rat nervous system after exposure to 2,5-hexanedione. Journal of Neurochemistry 1991, 57:1437-1444.
26. Leventopoulos M., Ruedi-Bettschen D., Knuesel I., Feldon J., Pryce C.R., Opacka-Juffry J. Long-term effects of early life deprivation on brain glia in Fischer rats. Brain Research 2007, 1142:119-126.
27. Lycke J.N., Karlsson J.E., Andersen O., Rosengren L.E. Neurofilament protein in cerebrospinal fluid: a potential marker of activity in multiple sclerosis. Journal of Neurology, Neurosurgery and Psychiatry 1998, 64:402-404.
28. Malmestrom C., Haghighi S., Rosengren L., Andersen O., Lycke J. Neurofilament light protein and glial fibrillary acidic protein as biological markers in MS. Neurology 2003, 61:1720-1725.
29. Miguel-Hidalgo J.J., Baucom C., Dilley G., Overholser J.C., Meltzer H.Y., Stockmeier C.A., Rajkowska G. Glial fibrillary acidic protein immunoreactivity in the prefrontal cortex distinguishes younger from older adults in major depressive disorder. Biological Psychiatry 2000, 48:861-873.
30. Muller M.B., Lucassen P.J., Yassouridis A., Hoogendijk W.J., Holsboer F., Swaab D.F. Neither major depression nor glucocorticoid treatment affects the cellular integrity of the human hippocampus. European Journal of Neuroscience 2001, 14:1603-1612.
31. Naarding P., Schoevers R.A., Janzing J.G., Jonker C., Koudstaal P.J., Beekman A.T. A study on symptom profiles of late-life depression: the influence of vascular, degenerative and inflammatory risk-indicators. Journal of Affective Disorders 2005, 88:155-162.
32. Nitsch R.M., Deng M., Growdon J.H., Wurtman R.J. Serotonin 5-HT2a and 5-HT2c receptors stimulate amyloid precursor protein ectodomain secretion. The Journal of Biological Chemistry 1996, 271:4188-4194.
33. Norgren N., Rosengren L., Stigbrand T. Elevated neurofilament levels in neurological diseases. Brain Research 2003, 987:25-31.
34. Norgren N., Sundstrom P., Svenningsson A., Rosengren L., Stigbrand T., Gunnarsson M. Neurofilament and glial fibrillary acidic protein in multiple sclerosis. Neurology 2004, 63:1586-1590.
35. Palsson S., Larsson L., Tengelin E., Waern M., Samuelsson S., Hallstro T., Skoog I. The prevalence of depression in relation to cerebral atrophy and cognitive performance in 70- and 74-year-old women in Gothenburg. The Women's Health Study. Psychological Medicine 2001, 31:39-49.
36. Reines A., Cereseto M., Ferrero A., Bonavita C., Wikinski S. Neuronal cytoskeletal alterations in an experimental model of depression. Neuroscience 2004, 129:529-538.
37. Robert S.J., Zugaza J.L., Fischmeister R., Gardier A.M., Lezoualc'h F. The human serotonin 5-HT4 receptor regulates secretion of non-amyloidogenic precursor protein. The Journal of Biological Chemistry 2001, 276:44881-44888.
38. Rosengren L.E., Wikkelso C., Hagberg L. A sensitive ELISA for glial fibrillary acidic protein: application in CSF of adults. Journal of Neuroscience Methods 1994, 51:197-204.
39. Rosengren L.E., Karlsson J.E., Karlsson J.O., Persson L.I., Wikkelso C. Patients with amyotrophic lateral sclerosis and other neurodegenerative diseases have increased levels of neurofilament protein in CSF. Journal of neurochemistry 1996, 67:2013-2018.
40. Rosengren L.E., Karlsson J.E., Sjogren M., Blennow K., Wallin A. Neurofilament protein levels in CSF are increased in dementia. Neurology 1999, 52:1090-1093.
41. Si X., Miguel-Hidalgo J.J., O'Dwyer G., Stockmeier C.A., Rajkowska G. Age-dependent reductions in the level of glial fibrillary acidic protein in the prefrontal cortex in major depression. Neuropsychopharmacology 2004, 29:2088-2096.
42. Sjogren M., Blomberg M., Jonsson M., Wahlund L.O., Edman A., Lind K., Rosengren L., Blennow K., Wallin A. Neurofilament protein in cerebrospinal fluid: a marker of white matter changes. Journal of Neuroscience Research 2001, 66:510-516.
43. Webster M.J., Knable M.B., Johnston-Wilson N., Nagata K., Inagaki M., Yolken R.H. Immunohistochemical localization of phosphorylated glial fibrillary acidic protein in the prefrontal cortex and hippocampus from patients with schizophrenia, bipolar disorder, and depression. Brain, Behavior, and Immunity 2001, 15:388-400.
44. Webster M.J., O'Grady J., Kleinman J.E., Weickert C.S. Glial fibrillary acidic protein mRNA levels in the cingulate cortex of individuals with depression, bipolar disorder and schizophrenia. Neuroscience 2005, 133:453-461.
45. Yamasaki H., Itakura C., Mizutani M. Hereditary hypotrophic axonopathy with neurofilament deficiency in a mutant strain of the Japanese quail. Acta Neuropathologica (Berl) 1991, 82:427-434.
46. Zachrisson O.C., Balldin J., Ekman R., Naesh O., Rosengren L., Agren H., Blennow K. No evident neuronal damage after electroconvulsive therapy. Psychiatry Research 2000, 96:157-165.
47. Zetterberg H., Hietala M.A., Jonsson M., Andreasen N., Styrud E., Karlsson I., Edman A., Popa C., Rasulzada A., Wahlund L.O., Mehta P.D., Rosengren L., Blennow K., Wallin A. Neurochemical aftermath of amateur boxing. Archives of Neurology 2006, 63:1277-1280.
48. Zhang Z., Casey D.M., Julien J.P., Xu Z. Normal dendritic arborization in spinal motoneurons requires neurofilament subunit L. Journal of Comparative Neurology 2002, 450:144-152.
49. Zhu Q., Couillard-Despres S., Julien J.P. Delayed maturation of regenerating myelinated axons in mice lacking neurofilaments. Experimental Neurology 1997, 148:299-316.